News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alerion Biomedical, Inc. Release: Fenestra(TM), The Leading Contrast Agent For microCT, To Be Featured In Multiple Presentations At The Medical Imaging 2005 Symposium Held By The International Society For Optical Engineering


10/19/2005 5:12:41 PM

SAN DIEGO, Feb. 10 /PRNewswire/ -- Results using Fenestra(TM), a family of contrast agents for microCT and CT imaging developed by Alerion Biomedical Inc., will be featured in presentations by leading academic researchers during the Medical Imaging Symposium held February 12 - 17 in San Diego, CA as part of the annual meeting of SPIE - The International Society for Optical Engineering.

Fenestra overcomes the low soft tissue contrast inherent in microCT imaging. In vivo contrast enhancement is available through two unique formulations: Fenestra(TM) VC for prolonged contrast enhancement in the vasculature and Fenestra(TM) LC for long-lasting hepatobiliary contrast enhancement. In addition to providing superior visualization, Fenestra is compatible with repeat administration, eliminating the need to sacrifice and assay multiple animals during longitudinal studies.

"The popularity of Fenestra continues to increase as more researchers learn about the value the technology brings to small animal imaging in particular using computed tomography," said Dr. Douglas Bakan Alerion's Vice President of Business Development. "We are pleased to offer a product line that makes a significant impact in both the quality and the types of studies that can be performed with CT and microCT imaging."

More information about Alerion and the Fenestra product line, including an offer for free samples, is available at http://www.alerionbio.com/.

About Alerion:

Alerion Biomedical Inc. develops and commercializes novel technologies for improving the detection, treatment, and monitoring of disease processes at the molecular level. Alerion is rapidly emerging as a leader in developing innovative solutions to challenges in molecular medicine through its unique platform technologies for enhanced in vivo imaging and precisely targeted delivery of therapeutic agents.

Alerion Biomedical Inc.

CONTACT: Douglas Bakan, PhD, Vice President, Business Development,+1-858-558-2191 ext. 202, dbakan@alerionbio.com, or Michael Beeuwsaert,President & CEO, +1-858-558-2191 ext. 210, info@alerionbio.com, both ofAlerion Biomedical Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES